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Figure 2. Overall Survival of AML Patients by Remission Status.
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were 17 and 19 days, respectively. Grade 3-4 aGVHD occurred
in 20% and 14% in the total cohort and AML subset respec-
tively. cGVHD developed in 54% (17% extensive stage) and
35% (8% extensive stage) of pts in the total cohort and AML
subset respectively.
The 5 year OS for the entire cohort was 29% [95% CI (23%-
36%)], and varied by diagnosis (Fig 1). NRM at 100 days was
17% [95% CI (13%-23%)].
On univariate analysis of the entire cohort, only 1-antigen
mismatch [HR 1.96, p-value¼0.01] and KPS<80 [HR 10.66, p-
value <0.001] were associated with worse OS. In the AML
cohort, active disease at HSCT (HR 2.43 p¼0.001), failure to
engraft (HR 4.84 p<0.001), and grade 3-4 aGVHD (4.08
p<0.001) were associated with worse OS. In multivariate
analysis after stepwise selection, advanced age (aHR 1.36,
p¼0.04), active disease (aHR 2.46, p-value¼0.003) (Fig 2),
engraftment syndrome (aHR 43, p¼0.001) and grade 3-4
aGVHD (aHR 5.23 p<0.001) were associated with worse OS.
Conclusions:We report over a decade of experiencewith the
PPT regimen. OS and low NRM are similar to other reported
RIC regimens despite high rates of active disease at HSCT.
Rates of severe acute and extensive chronic GVHD were low.
PPT remains a viable regimen for pts not eligible for mye-
loablative conditioning.15
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Background: A compromised immune system of Hemato-
poietic Cell Transplantation (HCT) recipients early aftertransplantation renders them vulnerable to a heightened
risk of reactivation of otherwise latent viral infections. Un-
controlled reactivation of Epstein-Barr virus (EBV) is one of
such events that can culminate into post-transplant lym-
phoproliferative disorder (PTLD), a complication associated
with high risk of mortality. Recovering within weeks after
transplantation and being ﬁrst in the line of defense against
viral infections, natural killer (NK) cells are deemed
important in the immune surveillance against the reac-
tivation and complications of EBV. Their role however re-
mains elusive. The complexity of NK cell response is a
function of a series of activating and inhibitory cell surface
receptors known as Killer Immunoglobulin-like Receptors
(KIR), which sense perturbations in HLA expression after
viral transformation of the target cell. Here, we set out to
determine whether and how KIR gene repertoire of HCT
donors and/or recipients inﬂuences the development of
PTLD after allo-HCT.
Study Design: KIR gene repertoires of 356 HLA-matched
donor-recipient pairs of ﬁrst allo-HCT and 50 healthy in-
dividuals were determined by Luminex based rSSO method.
The KIR genotypes were classiﬁed into AA and B/x genotypes.
Presence or absence of one or more haplotype-B deﬁning KIR
genes further identiﬁed genotypes for centromeric (Cen) and
telomeric (Tel) parts of the KIR locus. PBMNCs from 50 KIR-
genotyped healthy volunteers were stimulated with EBV-
transformed cells to enumerate EBV-induced NK cell
response (degranulation and/or IFNg production) as a func-
tion of KIR gene distribution using a multicolor ﬂow
cytometry-based assay. Effect of KIR gene repertoires on
development of PTLD was analyzed using binomial
competing risks regression statistics.
Results: Donor telomeric A motifs (Tel-A, KIR3DL1+ve-
KIR2DS4+ve; KIR3DS1/2DS1+/-ve), strongly protected against
PTLD (p¼0.0002, SHR¼0.21; Figure 1A). The protection of
donor Tel-A motifs against PTLD shows a dose dependent
effect as cumulative incidence of PTLD in HCT recipients
receiving graft from donors carrying two Tel-A motifs, one
Tel-A motif and no Tel-A motif was 6%, 11% and 19%
respectively. Further, the numbers of EBV induced
functional NK cell subsets were signiﬁcantly higher in
individuals with than without KIR genotypes containing
Tel-A motifs (Figure 1B).
Figure 1. Inﬂuence of KIR Telomeric-A (Tel-A) motifs on [A] the development
of PTLD after allogeneic HCT; and [B] NK cell response against EBV trans-
formed cells.
Table
Characteristics of 2nd UCBT
Characteristics of 2ndUCBT
Gender N %
Male 30 83.3
Primary Disease
Heme malignancy 16 44.4
Inherited metabolic disease 10 27.8
Marrow failure 4 11.1
Immunodeﬁciency 3 8.3
Hemoglobinopathy 3 8.3
Reason for 2nd UCBT
Primary graft failure 25 69.4
Late graft failure 3 8.33
Autologous recovery 8 22.2
Demographics median range
Age at 2nd UCBT (years) 7.4 1.5-20.9
Weight at 2nd UCBT (kg) 22.9 9.0-108.0
Time from 1st to 2nd UCBT (days) 61.5 42-3454
Cell Dose (n[39)
Cryopreserved TNCs x 107/kg 5.6 1.3-21.9
Reinfused TNCs x 107/kg 4.6 1.1-18.1
Reinfused CD34+ x 105/kg 1.4 0.1-15.0
Reinfused CD3+ x 106/kg 9.1 1.5-34.4
Reinfused CFUs x 104/kg 5.7 0.0-175.4
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repertoire has a profound effect on the development of PTLD.
KIR genotype based identiﬁcation of HCT donor-recipient
pairs at high risk of developing PTLD will enable closer
monitoring of EBV DNAemia and facilitate prompt therapy.Figure.16
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Background: In the past 20 years, use of UCBT has improved
access to transplantation, particularly in children and ethnic
minorities. Rapid donor availability, partial HLA matching
and low incidence of graft versus host disease (GVHD) are
important advantages. UCBT outcomes have signiﬁcantly
improved in the last decade due to better graft availability
and donor selection. However, a small fraction of recipients
develop auto-recovery or graft failure and are candidates for
a second transplant. In most cases, due to urgency and
original limitations in donor choices, another cord blood unit
(CBU) is the best option for these children.Methods: Retrospective analysis of all pediatric patients
(<21 years) undergoing UCBT at Duke between 1995 and
2013 who subsequently received a second UCBT due to
graft failure or auto-recovery after the ﬁrst UCBT (n¼36)
was conducted. Patients requiring second transplants for
relapse were excluded. Kaplan-Meier estimates of overall
survival (OS) and cumulative incidence (CI) of engraftment
and GVHD were calculated. All received reduced intensity
conditioning for the second transplant. The most common
prep regimen was cyclophosphamide 60mg/kg x 2 and
equine ATG 30mg/kg x 3 (n¼15). Single cord (n¼28),
double cord (n¼3) or cord +haplo graft (n¼5) were the
donor sources. Demographic, disease and graft character-
istics are shown in the Table.
Results: The OS at 100 days, 1 year and 5 years was 50.0%,
37.1% and 33.3% respectively. Mortality was lower for pa-
tients transplanted after 2007, but the difference was not
statistically signiﬁcant (p¼0.33) (see Figure). Median time to
neutrophil (ANC 500) and platelet (50K) engraftments were
27 (range, 12-94) and 98 days (range, 37-434) respectively.
The probability of neutrophil engraftment at day 42 was
64.3%. The CI of grades II-IV and grades III-IV acute GVHD, at
100 days was 47.1% and 31.3% respectively. Extensive/chronic
GVHD was seen in 3 patients (CI¼13.6%).
